Carbonic anhydrase (CA) is an enzyme that assists rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions. It is abundant in all mammalian tissues. Because of its functionality, it has become an important diagnostic marker for various cancers, most notably renal cell carcinoma (RCC). There are many genes that are inducible by hypoxia, via HIF-1 alpha. CA IX is one of the most inducible genes because of its stability and location within the membrane. Carbonic anhydrases have a widespread role in regulating pH in normal tissues, by regulating hydrogen ion (H+) flux. The pH is important in cell death under hypoxia, thus a blockade of CA IX results in increased cell death under hypoxia. Therefore, CA IX has become a reliable histochemical marker of hypoxia.
Abbkine CA IX Monoclonal Antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. The antibody detects endogenous CA IX proteins in human samples and was validated for WB, IP, IF, IHC-p. Abbkine suggested the starting dilutions for WB was 1:3000, IP: 1:200, IF: 1:200, IHC-p: 1:200, but the optimal working dilutions should be determined experimentally by the end user. The concentration of the antibody is 1mg/ml.
The CA IX Monoclonal Antibody is performing very well for our research clinical trials. We used it on human lung cancer tissue for clinical trials to verify results that we had gotten from an antibody from another manufacturer. The Abbkine CA IX Monoclonal Antibody worked even better. It was able to detect CA IX proteins . We first tried the recommended IHC-p: 1:200 concentration and it worked great. The signal produced was very strong and clear. The sensitivity of the antibody was also perfect. Apart from the performance of the antibody, it was also great to be able to order the antibody in trial-sized quantities.